3.5-6.5万
鑫叁零叁产业园315室
作为申办方医学Owner,确保临床开发的医学价值、终点选择与证据链可被监管与合作方认 可。
Serve as sponsor medical owner ensuring clinical value, endpoints, and evidence chain meet regulatory and partner expectations.
汇报研发负责人/项目组合负责人;紧密协作临床运营、统计、注册、药物警戒PV
(Pharmacovigilance,药物警戒)、CMC(Chemistry, Manufacturing and Controls,化学/生产/质 量)、医学写作MW(Medical Writing,医学写作)、CRO。
Report to R&D/Portfolio lead; partner with ClinOps, Biostats, RA, PV, CMC, MW and CROs.
2. 牵头临床方案关键医学内容:疾病背景、未满足需求、获益风险(benefit-risk)论证、终点医学合理性。
3. 指导并审核关键临床文件:方案、IB(Investigator’s Brochure,研究者手册)、CSR(Clinical Study Report,临床研究报告)医学章节、监管会议资料。
4. KOL与中心管理:医学沟通、研究者培训要点、医学问题答疑;支撑受试者招募医学策略。
5. 支持安全性评估:与PV联动识别风险、制定监测与处置建议;参与DSMB(Data Safety Monitoring Board,数据安全监察委员会)相关工作(如适用)。
6. 支持BD(Business Development,商务拓展)与对外合作:医学差异化卖点、竞争格局解读、尽调问答。
Key responsibilities (EN)
1.Own and maintain TPP translating it into indication/endpoints/criteria/dose & risk strategy.
2.Lead medical rationale for protocol and benefit-risk.
3.Review protocol, IB, CSR medical sections, and agency meeting decks.
4.KOL/site medical engagement and training; support recruitment medical strategy.
5.Partner with PV on safety risk monitoring/mitigation; support DSMB as needed.
6.Support BD due diligence with medical positioning and competitive insights.
教育:临床医学/药学/相关专业硕士及以上(MD优先)。
经验:5–10年创新药临床开发/医学事务经验;主导过至少1项II期及以上研究医学工作者优先。 能力:优秀医学写作与表达;能独立判断终点与方案关键取舍;熟悉GCP(Good Clinical Practice,药物临 床试验质量管理规范)与相关指南。
语言:可用英文进行会议沟通与文档审阅者优先。
Qualifications (EN)
MS/PhD/MD in relevant field; 5–10 yrs in clinical development/medical; II+ phase experience preferred; strong medical writing, decision-making, GCP knowledge; English proficiency preferred.
以担保或任何理由索取财物,扣押证照,均涉嫌违法,请提高警惕